Allworth Financial LP Raises Stock Position in DexCom, Inc. $DXCM

Allworth Financial LP raised its holdings in DexCom, Inc. (NASDAQ:DXCM) by 33.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,807 shares of the medical device company’s stock after purchasing an additional 961 shares during the quarter. Allworth Financial LP’s holdings in DexCom were worth $332,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Andra AP fonden acquired a new stake in shares of DexCom during the 2nd quarter valued at about $26,000. Zions Bancorporation National Association UT acquired a new position in DexCom in the 1st quarter worth about $27,000. Anderson Financial Strategies LLC purchased a new position in DexCom during the first quarter worth approximately $37,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in DexCom in the second quarter valued at approximately $45,000. Finally, Atlantic Union Bankshares Corp acquired a new position in shares of DexCom during the 2nd quarter worth approximately $70,000. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Trading Down 2.8%

NASDAQ:DXCM opened at $58.06 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The business’s 50-day moving average is $67.25 and its two-hundred day moving average is $77.26. The firm has a market capitalization of $22.64 billion, a PE ratio of 40.32, a price-to-earnings-growth ratio of 1.43 and a beta of 1.40. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $93.25.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same period in the previous year, the company earned $0.45 earnings per share. The company’s revenue for the quarter was up 21.6% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. Research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on DXCM shares. The Goldman Sachs Group decreased their target price on DexCom from $104.00 to $89.00 and set a “buy” rating on the stock in a research report on Wednesday, October 1st. Oppenheimer lowered DexCom from an “outperform” rating to a “market perform” rating in a research report on Monday, September 8th. Morgan Stanley dropped their target price on shares of DexCom from $89.00 to $63.00 and set an “equal weight” rating on the stock in a research report on Monday, November 10th. Robert W. Baird set a $82.00 price objective on DexCom in a research note on Friday, October 31st. Finally, Truist Financial reissued a “buy” rating and set a $82.00 price target (down from $94.00) on shares of DexCom in a report on Monday, November 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $87.62.

Insider Activity

In other DexCom news, EVP Sadie Stern sold 1,466 shares of the firm’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the sale, the executive vice president directly owned 105,223 shares in the company, valued at approximately $8,417,840. This trade represents a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Bridgette P. Heller sold 1,012 shares of the stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total value of $58,766.84. Following the transaction, the director directly owned 27,031 shares of the company’s stock, valued at approximately $1,569,690.17. The trade was a 3.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 7,093 shares of company stock valued at $447,792 over the last quarter. Corporate insiders own 0.32% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.